LONDON – Pharmaceuticals Sanofi and GlaxoSmithKline have agreed to provide 200 million doses of their potential Covid-19 vaccine to the COVAX Facility, a collaboration designed to give countries around the world equal access to the coronavirus vaccine.
The Sanofi-GSK vaccine is in the early stages of trials, with results expected in early December. The drug companies said today that they plan to begin phase three of the trials at the end of the year and will seek regulatory approval for the product in the first half of 2021.
COVAX Facility is a mechanism that is part of COVAX, a coalition of governments, health organizations, companies and charities that work to accelerate the development of vaccines against Covid-19.
”Addressing a global health crisis of this magnitude requires unique partnerships. The commitment we announced today to the COVAX Facility can help us together to have a better chance of controlling the pandemic, “said Thomas Triomphe, director of Sanofi’s vaccines unit.
Nearly 44 million cases of coronavirus have been confirmed worldwide, and 1.16 million patients have died from the virus, according to a tally by Johns Hopkins University. Experts say that the true scope of the pandemic is much greater due to the limited number of screening tests that are carried out, the mild cases that go unnoticed and the concealment of positives by some governments.